HOXD13 and non-small cell lung carcinoma: A study on patients with non-small cell lung cancer investigated the change in sPD1 concentration in the blood over the course of treatment with erlotinib, up until the development of clinical resistance, showed that patients with increased sPD1 levels during erlotinib treatment were associated with prolonged progression free survival and overall survival [17].